Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Liminatus Pharma Inc. (LIMN) had Normalized Pre-Tax Income of $-10.21M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.21M |
|
-- |
|
-- |
|
$2.97M |
|
$-2.97M |
|
$-7.24M |
|
$-10.21M |
|
|
Normalized Pre-Tax Income |
$-10.21M |
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-2.97M |
|
$-2.97M |
|
0.48M |
|
0.48M |
|
$-21.50 |
|
$-21.50 |
|
| Balance Sheet Financials | |
$0.50M |
|
$0.01M |
|
$0.01M |
|
$0.51M |
|
$10.30M |
|
-- |
|
$0.03M |
|
$10.33M |
|
$-9.81M |
|
$-9.81M |
|
$-9.81M |
|
0.54M |
|
| Cash Flow Statement Financials | |
$-9.96M |
|
$-0.79M |
|
$11.03M |
|
$0.06M |
|
$0.34M |
|
$0.28M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.05 |
|
-- |
|
-- |
|
-- |
|
-0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
103.99% |
|
103.99% |
|
-1990.37% |
|
103.99% |
|
$-18.13 |
|
$-21.00 |
|
$-20.97 |
|